Description: <p><b>Carnosic acid</b> (CA) is a rosemary- and sage-derived phenolic diterpene that functions as a redox-active, pro-electrophilic phytochemical. It is best classified as a natural product / nutraceutical lead rather than an approved anticancer drug. Standard abbreviation: CA. Its most defensible mechanistic identity is bifunctional redox modulation: oxidation-enabled KEAP1 sensing with NRF2 activation in stress-responsive normal tissues, but context-dependent ROS elevation and stress-pathway disruption in cancer cells. At present, its oncology relevance is predominantly experimental, with no established regulatory deployment as a cancer therapeutic.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Oxidation-dependent KEAP1 modification and NRF2 pathway activation</li>
<li>Cancer-cell ROS elevation with stress-threshold apoptosis</li>
<li>Mitochondrial apoptotic signaling and ER-stress coupling</li>
<li>JAK2/Src/STAT3 suppression</li>
<li>PI3K / AKT / mTOR growth-survival pathway suppression</li>
<li>Anti-angiogenic and anti-migratory effects</li>
<li>AMPK-linked autophagy / metabolic stress signaling in some models</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> CA is lipophilic and orally bioavailable in animal studies, but exposure is formulation-dependent and strongly shaped by oxidation, metabolism, and matrix effects. Brain distribution has been reported after rosemary-extract administration in rodents, supporting CNS relevance more than robust systemic oncology exposure. Translation is constrained by chemical lability and by the likelihood that many direct anticancer in-vitro concentrations are difficult to sustain clinically without optimized delivery.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Much of the anticancer literature uses roughly 10–50 µM, sometimes higher. That range is mechanistically useful but often above plausible exposure from ordinary dietary rosemary intake, and likely above many supplement-level free-plasma exposures. Accordingly, cancer-cell killing data should be interpreted as lead-compound pharmacology, not as proof that culinary or standard nutraceutical exposure reproduces the same tumor effects in humans.</p>
<p><b>Clinical evidence status:</b> Preclinical. There are cell-line and animal data across multiple tumor types, plus combination studies suggesting chemosensitization in selected models, but no robust human RCT evidence establishing CA as a stand-alone or standard adjunct anticancer therapy.</p>
<b>Carnosic acid (CA)</b> natural antioxidant diterpene found in rosemary and sage. <br>
-used in the food industry as a flavouring agent and to provide a major source of natural antioxidants<br>
<br>
Pathways:<br>
-Inhibit the PI3K/Akt pathway, which is typically overactivated in many cancers.<br>
-inhibits ERK activation, reducing cell proliferation.<br>
-JNK and p38 MAPK: Activation of these kinases by carnosic acid may contribute to stress responses leading to cell cycle arrest or apoptosis.<br>
-Block the activation of NF-κB,<br>
-Induce apoptosis by disturbing mitochondrial membrane potential, leading to the release of cytochrome c and activation of caspases.<br>
-Dual role: as an antioxidant under normal conditions and, in the context of cancer cells, it can induce ROS production beyond a critical threshold.<br>
-Interfere with STAT3 activation, <br>
-AMPK Activation<br>
-Inhibition of Angiogenesis and Metastasis<br>
-Induction of endoplasmic reticulum (ER) stress<br>
<br>
-At lower concentrations, carnosic acid might exhibit antioxidant activity, protecting cells by scavenging free radicals. However, cancer cells often have altered redox balances which can make them more vulnerable to further ROS increases.<br>
-While carnosic acid has antioxidant properties in some contexts, it is typically observed to have a prooxidant effect in cancer cells under specific conditions, particularly at concentrations that favor ROS accumulation and the subsequent induction of apoptotic cell death<br>
<br>
-10-100uM, or 10–100 mg/kg for achieving anticancer effects.<br>
-Typically available in standardized rosemary extracts.<br>
<h3>Carnosic Acid (CA) — Pathway / Axis Effects (Cancer vs Normal)</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>KEAP1 / NRF2 electrophile sensing</td>
<td>↔ / ↑ cytoprotection (context-dependent)</td>
<td>↑ antioxidant defense</td>
<td>P→G</td>
<td>Stress-response activation</td>
<td>Core identity of CA is as a pro-electrophilic catechol diterpene that becomes more reactive after oxidation; this is central in normal-cell protection but can be double-edged in NRF2-dependent tumors.</td>
</tr>
<tr>
<td>2</td>
<td>ROS increase</td>
<td>↑ ROS (dose-dependent) → apoptosis</td>
<td>↓ oxidative burden or buffered response</td>
<td>P/R</td>
<td>Redox-threshold killing</td>
<td>Best viewed as bifunctional redox pharmacology: antioxidant-compatible at lower or protective settings, but pro-oxidant in stressed malignant cells at effective anticancer doses.</td>
</tr>
<tr>
<td>3</td>
<td>Mitochondria / intrinsic apoptosis</td>
<td>ΔΨm ↓; cytochrome c release ↑; caspase cleavage ↑</td>
<td>↔ / protective</td>
<td>R</td>
<td>Apoptosis induction</td>
<td>Mitochondrial disruption is repeatedly reported downstream of ROS accumulation.</td>
</tr>
<tr>
<td>4</td>
<td>ER stress / CHOP axis</td>
<td>↑ ER stress; CHOP ↑</td>
<td>↔</td>
<td>R/G</td>
<td>Stress-mediated cell death</td>
<td>Usually better interpreted as a secondary amplifier of redox injury rather than the initiating event.</td>
</tr>
<tr>
<td>5</td>
<td>STAT3 signaling</td>
<td>↓ phosphorylation / activity</td>
<td>↔</td>
<td>R/G</td>
<td>Survival and inflammatory signaling suppression</td>
<td>Supported in colon and other models; important where STAT3 dependence is strong.</td>
</tr>
<tr>
<td>6</td>
<td>PI3K / AKT / mTOR</td>
<td>↓ signaling</td>
<td>↔ / sometimes adaptive support</td>
<td>R/G</td>
<td>Growth arrest and proliferation suppression</td>
<td>Commonly reported, but usually better treated as downstream or parallel network suppression than as the single primary target.</td>
</tr>
<tr>
<td>7</td>
<td>AMPK / autophagy</td>
<td>↑ AMPK; autophagy ↑</td>
<td>↔ / metabolic support</td>
<td>R/G</td>
<td>Metabolic stress signaling</td>
<td>Mechanistically relevant in some recent models; role may be cytostatic or context-dependent rather than uniformly lethal.</td>
</tr>
<tr>
<td>8</td>
<td>Angiogenesis / migration / invasion</td>
<td>↓ endothelial proliferation; migration ↓; invasion ↓</td>
<td>↔</td>
<td>G</td>
<td>Anti-metastatic and anti-angiogenic restraint</td>
<td>Supported by endothelial assays and in vivo angiogenesis models; therapeutically relevant but likely secondary to broader stress signaling.</td>
</tr>
<tr>
<td>9</td>
<td>Ferroptosis</td>
<td>↑ lipid peroxidation; GSH ↓; xCT ↓; ferroptotic death ↑ (model-dependent)</td>
<td>↔ / uncertain</td>
<td>R/G</td>
<td>Iron-dependent oxidative cell death</td>
<td>merits inclusion as a secondary row because direct evidence exists in cisplatin-resistant OSCC, where CA promoted ferroptosis while suppressing NRF2/HO-1/xCT signaling; still too niche to rank among the core top mechanisms.</td>
</tr>
<tr>
<td>10</td>
<td>Ca²⁺ dysregulation</td>
<td>↑ cytosolic Ca²⁺ overload (combination-dependent)</td>
<td>↔</td>
<td>P/R</td>
<td>Calcium-driven apoptosis support</td>
<td>contextual lower-rank row: the strongest evidence is for CUR + CA synergy in AML, where sustained Ca²⁺ elevation from intracellular stores drove apoptosis. It is not yet a broadly established CA-alone pan-cancer mechanism.</td>
</tr>
<tr>
<td>11</td>
<td>HIF-1α / glycolytic adaptation</td>
<td>↓ (model-dependent)</td>
<td>↔</td>
<td>G</td>
<td>Hypoxic adaptation restraint</td>
<td>Plausible but less uniformly established than redox, apoptosis, STAT3, and ferroptosis-linked findings.</td>
</tr>
<tr>
<td>12</td>
<td>Chemosensitization</td>
<td>↑ sensitivity (model-dependent)</td>
<td>↔ / unknown clinical net</td>
<td>G</td>
<td>Adjunctive leverage</td>
<td>Supported preclinically with selected agents, including platinum-resistant settings, but schedule and tumor redox state remain important interpretation variables.</td>
</tr>
<tr>
<td>13</td>
<td>Clinical Translation Constraint</td>
<td>Exposure ceiling; formulation dependence; tumor heterogeneity</td>
<td>Potential tissue protection</td>
<td>—</td>
<td>PK-limited translation</td>
<td>Most direct tumor-killing data rely on concentrations that may exceed realistic free systemic exposure from non-optimized use; tumor NRF2 status remains an important variable.</td>
</tr>
</table>
<p><b>TSF legend:</b> P: 0–30 min (primary/rapid effects; direct redox interactions) · R: 30 min–3 hr (acute signaling + stress responses) · G: >3 hr (gene-regulatory adaptation; phenotype outcomes)</p>
<br>
<br>
<h3>AD and Carnosic Acid</h3>
<p><b>Carnosic acid</b> (CA) is a rosemary- and sage-derived phenolic diterpene with significant Alzheimer’s disease relevance, chiefly as a pro-electrophilic neuroprotective agent rather than as a direct anti-amyloid drug. It is best classified in AD as a pleiotropic small-molecule neuroprotective natural product that is oxidatively activated under conditions of cellular stress, enabling selective KEAP1/NRF2 pathway engagement. Standard abbreviation: CA. The strongest AD rationale is reduction of oxidative stress, neuroinflammation, amyloidogenic processing, and downstream neuronal injury, with supporting animal and cell data and recent prodrug work, but no established human efficacy standard or approved AD deployment.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Oxidation-dependent KEAP1 modification and NRF2 pathway activation</li>
<li>Suppression of glia-driven neuroinflammation</li>
<li>Reduction of amyloidogenic burden via α-secretase bias and lower Aβ42/Aβ43 production</li>
<li>Mitochondrial and anti-apoptotic neuronal protection</li>
<li>Reduction of tau hyperphosphorylation</li>
<li>NLRP3 inflammasome restraint</li>
<li>Synaptic / neurotrophic support and cognitive preservation</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Oral rosemary-extract studies in rodents detected small quantities of CA and trace CA metabolites in brain, supporting BBB-relevant exposure, but absolute brain exposure appears limited and formulation-sensitive. This is one reason newer prodrug strategies such as diAcCA are being explored to improve brain delivery and disease-modifying potential.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Much of the mechanistic AD literature uses low-micromolar cell exposure, often in pretreatment paradigms. Those concentrations are pharmacologically informative, but they should not be assumed to arise from ordinary dietary rosemary intake. The AD case is therefore strongest as a brain-directed lead-compound / prodrug platform rather than proof that routine dietary exposure is sufficient.</p>
<p><b>Clinical evidence status:</b> Preclinical. There are multiple cell and animal studies supporting neuroprotection, anti-inflammatory effects, reduced amyloid-related pathology, and cognitive benefit, but there is no robust human RCT evidence establishing CA as an approved or standard AD therapy.</p>
<h3>AD mechanistic interpretation</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Modulation</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>KEAP1 / NRF2 electrophile sensing</td>
<td>↑</td>
<td>P→G</td>
<td>Endogenous antioxidant and cytoprotective program activation</td>
<td>This remains the core AD-relevant identity of carnosic acid. It is best understood as a pro-electrophilic compound activated under oxidative stress, making NRF2 the most central upstream mechanism.</td>
</tr>
<tr>
<td>2</td>
<td>ROS / oxidative stress</td>
<td>↓</td>
<td>R/G</td>
<td>Reduction of oxidative neuronal injury</td>
<td>Worth restoring as a top-ranked row because oxidative stress reduction is one of the most consistent AD-facing outcomes. Much of this likely sits downstream of NRF2 activation, but it is important enough phenotypically to rank separately.</td>
</tr>
<tr>
<td>3</td>
<td>NF-κB inflammatory signaling</td>
<td>↓</td>
<td>R/G</td>
<td>Suppression of neuroinflammatory transcription</td>
<td>This is cleaner and more pathway-specific than a generic glial inflammation row. It captures reduced inflammatory signaling in microglia and astroglia and fits well with the APP/PS1 anti-inflammatory data.</td>
</tr>
<tr>
<td>4</td>
<td>Amyloidogenic processing</td>
<td>↓ Aβ42 / Aβ43</td>
<td>R/G</td>
<td>Shift away from toxic amyloid production</td>
<td>Carnosic acid has direct evidence for induction of α-secretase activity and reduction of Aβ42/Aβ43 generation, so this deserves to remain a high-rank AD-specific mechanism.</td>
</tr>
<tr>
<td>5</td>
<td>Mitochondrial oxidative stress and neuronal apoptosis</td>
<td>↓</td>
<td>R/G</td>
<td>Neuronal survival support</td>
<td>In AD framing, mitochondrial stabilization and reduced apoptosis are protective outcomes downstream of oxidative-stress control rather than pro-death mechanisms as in cancer.</td>
</tr>
<tr>
<td>6</td>
<td>Tau hyperphosphorylation</td>
<td>↓</td>
<td>G</td>
<td>Restraint of tau-linked neuronal dysfunction</td>
<td>Supported, but overall the evidence base is not as central or as consistent as for NRF2, ROS, NF-κB, and amyloid processing.</td>
</tr>
<tr>
<td>7</td>
<td>NLRP3 inflammasome</td>
<td>↓</td>
<td>R/G</td>
<td>Innate immune overactivation restraint</td>
<td>Relevant, but probably best interpreted as part of the broader anti-inflammatory program downstream of redox and NF-κB control rather than a top initiating axis.</td>
</tr>
<tr>
<td>8</td>
<td>Synaptic plasticity / neurite support</td>
<td>↑</td>
<td>G</td>
<td>Cognitive resilience and network maintenance</td>
<td>This captures downstream functional preservation including neurite and synaptic support, but it is less mechanistically central than the upstream stress and inflammatory pathways.</td>
</tr>
<tr>
<td>9</td>
<td>Cholinergic dysfunction</td>
<td>↓ dysfunction</td>
<td>G</td>
<td>Functional neuronal preservation</td>
<td>Reasonable to include as a systems-level consequence, but not strong enough to rank above the main oxidative, inflammatory, amyloid, and mitochondrial axes.</td>
</tr>
<tr>
<td>10</td>
<td>Clinical Translation Constraint</td>
<td>↔</td>
<td>—</td>
<td>Brain exposure and formulation-limited translation</td>
<td>Native carnosic acid has credible brain-relevant pharmacology, but exposure is limited and formulation-sensitive; AD translation remains preclinical and increasingly prodrug-oriented.</td>
</tr>
</table>
<p><b>TSF legend:</b> P: 0–30 min · R: 30 min–3 hr · G: >3 hr</p>